Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.
Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.
Exp Hematol. 2021 Mar;95:23-30. doi: 10.1016/j.exphem.2021.01.004. Epub 2021 Jan 23.
Acute myeloid leukemia (AML) is a heterogeneous disease, yet clinically most patients present with pancytopenia resulting from bone marrow failure, predisposing them to life-threatening infections and bleeding. The mechanisms by which AML mediates hematopoietic suppression is not well known. Indeed, much effort has so far been focused on how AML remodels the bone marrow niche to make it a more permissive environment, with less focus on how the remodeled niche affects normal hematopoietic cells. In this perspective, we present evidence of the key role of the bone marrow niche in suppressing hematopoietic stem cells (HSCs) during leukemic progression and provide perspectives on how future research on this topic may be exploited to provide treatments for one of the key complications of AML.
急性髓系白血病（AML）是一种异质性疾病，但临床上大多数患者表现为骨髓衰竭导致的全血细胞减少，使他们容易发生危及生命的感染和出血。AML 介导造血抑制的机制尚不清楚。事实上，迄今为止，人们主要致力于研究 AML 如何重塑骨髓龛，使其成为一个更允许的环境，而较少关注重塑的龛如何影响正常造血细胞。从这个角度来看，我们提出了骨髓龛在白血病进展过程中抑制造血干细胞（HSCs）的关键作用的证据，并就如何利用这一主题的未来研究为 AML 的一个关键并发症提供治疗方法提供了一些观点。
